Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Palatin Technologies, Inc./ 10-Q

Quarterly Report · 10-Q

Palatin Technologies, Inc.

Quarterly Report

Filed Feb 14, 2023Accepted Feb 14, 2023, 4:30 PM ESTCIK 911216Accession 0001654954-23-001726
View company →Permanent SEC source ↗
Share

Company context

We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Current securities

PTNNASDAQ · EQUITY · Current
Historical securities (3)
PTNNYSE_AMERICAN · EQUITY · Historical · closed May 6, 2025PTNNYSE_AMERICAN · EQUITY · Historical · closed May 27, 2026PTNTOTC · EQUITY · Historical · closed Nov 17, 2025

Recent company filings

  1. 10-K filingSep 28, 2026
  2. SCHEDULE 13G/A filingAug 14, 2026
  3. Submission of Matters to a Vote of Security HoldersAug 3, 2026
  4. DEF 14A filingJun 25, 2026
  5. CERT filingMay 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗